These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35387932)

  • 21. Rare case of plasmablastic myeloma diagnosed on lung biopsy.
    Ayeboa-Sallah B; Qutab S; Grace R; Sharma N
    BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33741573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggressive Plasmablastic Myeloma With Extramedullary Cord Compression and Hyperammonemic Encephalopathy: Case Report and Literature Review.
    Dah K; Lavezo JL; Dihowm F
    Anticancer Res; 2021 Nov; 41(11):5839-5845. PubMed ID: 34732460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary plasma cell leukaemia (PCL) with plasmablastic morphology.
    Xu K; Nacheva E
    J Hematop; 2024 Jun; 17(2):117-119. PubMed ID: 38580782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphologic heterogeneity and plasmablastic transformation in advanced plasmacytic/plasmablastic myeloma: a study of 35 serial bone marrow biopsies in 9 patients.
    Paule B; Quillard J; Bennet P; Mariette X; Bisson M
    Nouv Rev Fr Hematol (1978); 1989; 31(3):203-8. PubMed ID: 2616267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple myeloma presenting initially with pleural effusion and a unique paraspinal tumor in the thorax.
    Yokoyama T; Tanaka A; Kato S; Aizawa H
    Intern Med; 2008; 47(21):1917-20. PubMed ID: 18981637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmablastic myeloma transformation of light-chain multiple myeloma.
    Pakasticali N; Hortin GL; Li JY
    J Clin Exp Hematop; 2024 Jun; 64(2):149-151. PubMed ID: 38684404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmablastic extramedullary plasmacytoma associated with Epstein-Barr virus arising in an immunocompetent patient with multiple myeloma.
    Sasaki S; Hashimoto K; Nakatsuka S; Hasegawa M; Nakano T; Nagata S; Kanakura Y; Hayashi N
    Intern Med; 2011; 50(21):2615-20. PubMed ID: 22041368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unilateral pleural effusion as a presenting manifestation of plasma cell myeloma (multiple myeloma): a case report.
    Dharan M
    Acta Cytol; 2010; 54(5 Suppl):780-2. PubMed ID: 21053539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.
    Møller HE; Preiss BS; Pedersen P; Kristensen IB; Hansen CT; Frederiksen M; Abildgaard N; Møller MB
    APMIS; 2015 Aug; 123(8):652-8. PubMed ID: 26152595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.
    Seegmiller AC; Wang HY; Hladik C; Chen W
    Arch Pathol Lab Med; 2011 Jun; 135(6):770-5. PubMed ID: 21631271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case of lymphadenopathy with lytic bone lesions.
    Kalantri SA; Nath UK; Banerjee D; Bhattacharyya M
    BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28320703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of plasma cell morphology in multiple myeloma.
    Paule B; Quillard J; Bisson M; Kahn MF; Massias P
    Nouv Rev Fr Hematol (1978); 1988; 30(4):209-12. PubMed ID: 3194186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
    Schneidawind C; Duerr-Stoerzer S; Faul C; Kanz L; Weisel K; Bethge W; Schneidawind D
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28470884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
    Ahn JS; Okal R; Vos JA; Smolkin M; Kanate AS; Rosado FG
    J Clin Pathol; 2017 Sep; 70(9):775-780. PubMed ID: 28249941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
    Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
    Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
    Leotta S; Pirosa MC; Markovic U; Scalise L; Bulla A; Sapienza G; Di Giorgio MA; Martino EA; Curto Pelle A; Leotta V; Milone G; Cupri A; Vaddinelli D; Villari L; Conticello C; Milone G
    Chemotherapy; 2019; 64(2):110-114. PubMed ID: 31533095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.